239 related articles for article (PubMed ID: 28804516)
1. The role of sebelipase alfa in the treatment of lysosomal acid lipase deficiency.
Erwin AL
Therap Adv Gastroenterol; 2017 Jul; 10(7):553-562. PubMed ID: 28804516
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome of a patient with lysosomal acid lipase deficiency and first results after initiation of treatment with Sebelipase alfa: A case report.
Soll D; Spira D; Hollstein T; Haberbosch L; Demuth I; Steinhagen-Thiessen E; Bobbert T; Spranger J; Kassner U
Mol Genet Metab Rep; 2019 Sep; 20():100479. PubMed ID: 31249784
[TBL] [Abstract][Full Text] [Related]
3. Long-term survival with sebelipase alfa enzyme replacement therapy in infants with rapidly progressive lysosomal acid lipase deficiency: final results from 2 open-label studies.
Vijay S; Brassier A; Ghosh A; Fecarotta S; Abel F; Marulkar S; Jones SA
Orphanet J Rare Dis; 2021 Jan; 16(1):13. PubMed ID: 33407676
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement therapy in lysosomal acid lipase deficiency (LAL-D): a systematic literature review.
Bashir A; Tiwari P; Duseja A
Ther Adv Rare Dis; 2021; 2():26330040211026928. PubMed ID: 37181111
[TBL] [Abstract][Full Text] [Related]
5. Persistent dyslipidemia in treatment of lysosomal acid lipase deficiency.
Pritchard AB; Strong A; Ficicioglu C
Orphanet J Rare Dis; 2020 Feb; 15(1):58. PubMed ID: 32093730
[TBL] [Abstract][Full Text] [Related]
6. Sebelipase alfa in children and adults with lysosomal acid lipase deficiency: Final results of the ARISE study.
Burton BK; Feillet F; Furuya KN; Marulkar S; Balwani M
J Hepatol; 2022 Mar; 76(3):577-587. PubMed ID: 34774639
[TBL] [Abstract][Full Text] [Related]
7. Sebelipase alfa: enzymatic replacement treatment for lysosomal acid lipase deficiency.
Paton DM
Drugs Today (Barc); 2016 May; 52(5):287-93. PubMed ID: 27376161
[TBL] [Abstract][Full Text] [Related]
8. Sebelipase Alfa: A Review in Lysosomal Acid Lipase Deficiency.
Frampton JE
Am J Cardiovasc Drugs; 2016 Dec; 16(6):461-468. PubMed ID: 27878737
[TBL] [Abstract][Full Text] [Related]
9. Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study.
Jones SA; Rojas-Caro S; Quinn AG; Friedman M; Marulkar S; Ezgu F; Zaki O; Gargus JJ; Hughes J; Plantaz D; Vara R; Eckert S; Arnoux JB; Brassier A; Le Quan Sang KH; Valayannopoulos V
Orphanet J Rare Dis; 2017 Feb; 12(1):25. PubMed ID: 28179030
[TBL] [Abstract][Full Text] [Related]
10. Novel treatment options for lysosomal acid lipase deficiency: critical appraisal of sebelipase alfa.
Su K; Donaldson E; Sharma R
Appl Clin Genet; 2016; 9():157-167. PubMed ID: 27799810
[TBL] [Abstract][Full Text] [Related]
11. Sebelipase alfa over 52 weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency.
Valayannopoulos V; Malinova V; Honzík T; Balwani M; Breen C; Deegan PB; Enns GM; Jones SA; Kane JP; Stock EO; Tripuraneni R; Eckert S; Schneider E; Hamilton G; Middleton MS; Sirlin C; Kessler B; Bourdon C; Boyadjiev SA; Sharma R; Twelves C; Whitley CB; Quinn AG
J Hepatol; 2014 Nov; 61(5):1135-42. PubMed ID: 24993530
[TBL] [Abstract][Full Text] [Related]
12. Hepatic cholesteryl ester accumulation in lysosomal acid lipase deficiency: non-invasive identification and treatment monitoring by magnetic resonance.
Thelwall PE; Smith FE; Leavitt MC; Canty D; Hu W; Hollingsworth KG; Thoma C; Trenell MI; Taylor R; Rutkowski JV; Blamire AM; Quinn AG
J Hepatol; 2013 Sep; 59(3):543-9. PubMed ID: 23624251
[TBL] [Abstract][Full Text] [Related]
13. Sebelipase alfa improves atherogenic biomarkers in adults and children with lysosomal acid lipase deficiency.
Wilson DP; Friedman M; Marulkar S; Hamby T; Bruckert E
J Clin Lipidol; 2018; 12(3):604-614. PubMed ID: 29628368
[TBL] [Abstract][Full Text] [Related]
14. Safety of sebelipase alfa for the treatment of lysosomal acid lipase deficiency.
Ezgü F
Expert Opin Drug Saf; 2022 Feb; 21(2):149-155. PubMed ID: 34664536
[TBL] [Abstract][Full Text] [Related]
15. Sebelipase alfa for lysosomal acid lipase deficiency: 5-year treatment experience from a phase 2 open-label extension study.
Malinová V; Balwani M; Sharma R; Arnoux JB; Kane J; Whitley CB; Marulkar S; Abel F
Liver Int; 2020 Sep; 40(9):2203-2214. PubMed ID: 32657505
[TBL] [Abstract][Full Text] [Related]
16. Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients with cholesteryl ester storage disease.
Balwani M; Breen C; Enns GM; Deegan PB; Honzík T; Jones S; Kane JP; Malinova V; Sharma R; Stock EO; Valayannopoulos V; Wraith JE; Burg J; Eckert S; Schneider E; Quinn AG
Hepatology; 2013 Sep; 58(3):950-7. PubMed ID: 23348766
[TBL] [Abstract][Full Text] [Related]
17. Childhood/adult-onset lysosomal acid lipase deficiency: A serious metabolic and vascular phenotype beyond liver disease-four new pediatric cases.
Poinsot P; Collardeau Frachon S; Restier L; Sérusclat A; Di Filippo M; Charrière S; Moulin P; Lachaux A; Peretti N
J Clin Lipidol; 2017; 11(1):167-177.e3. PubMed ID: 28391883
[TBL] [Abstract][Full Text] [Related]
18. Update on lysosomal acid lipase deficiency: Diagnosis, treatment and patient management.
Camarena C; Aldamiz-Echevarria LJ; Polo B; Barba Romero MA; García I; Cebolla JJ; Ros E
Med Clin (Barc); 2017 May; 148(9):429.e1-429.e10. PubMed ID: 28285817
[TBL] [Abstract][Full Text] [Related]
19. Managing Cardiovascular Risk in Lysosomal Acid Lipase Deficiency.
Maciejko JJ
Am J Cardiovasc Drugs; 2017 Jun; 17(3):217-231. PubMed ID: 28197978
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
